Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GPC falls on Orplatna miss

GPC (FSE:GPC; GPCB) fell EUR 4.74 (60%) to EUR 3.22 on Wednesday after additional data from the Phase III SPARC

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE